Literature DB >> 21861864

When to start dialysis in patients with acute kidney injury? When semantics and logic become entangled with expectations and beliefs.

Norbert Lameire1, Wim Vanbiesen, Raymond Vanholder.   

Abstract

Earlier initiation of dialysis may have a beneficial impact on survival of critically ill patients with acute kidney injury (AKI). A retrospective analysis in the previous issue of Critical Care showed that early initiation of renal replacement therapy (RRT), as defined by RIFLE criteria, was not associated with a reduction in hospital mortality. The retrospective character of many studies describing the results of early RRT initiation and the validity of RIFLE criteria to determine the need for dialysis can be questioned, in particular when urinary output is not considered. Initiating dialysis in AKI should be based on clinical criteria and not on serum creatinine or another serum/urine-based biomarker.

Entities:  

Mesh:

Year:  2011        PMID: 21861864      PMCID: PMC3387587          DOI: 10.1186/cc10280

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


In the previous issue of Critical Care, Chou and colleagues [1] report that early initiation of renal replacement therapy (RRT), as defined by RIFLE criteria, was not associated with reduction in hospital mortality in patients with acute kidney injury (AKI) and sepsis. The timing of initiation of RRT has been a controversial issue for many years in both patients suffering from chronic kidney disease [2] and those suffering from acute kidney disease [3]. A recently published systematic review and meta-analysis on this topic concluded that earlier initiation of RRT in critically ill AKI patients may have a beneficial impact on survival but that, in the absence of new evidence from suitably designed randomized trials, a definitive treatment recommendation cannot be made [3]. The idea that 'earlier' initiation of treatment should be beneficial stems from our belief that sometimes complex interventions may change the course of a disease. In the case of AKI and sepsis, it has been hypothesized that early dialysis in sepsis can reduce circulating levels of inflammatory substances and may therefore beneficially impact on the pathophysiological mechanisms of the disease. Unfortunately, the validity of this premise has never been proven, and existing evidence points rather in the opposite direction [4]. Both literature data and the currently published study once more confirm that patients with sepsis die with AKI rather than of AKI: no single indicator of renal function or kidney injury was predictive of mortality in the multivariate model as it was applied by Chou and colleagues [1]. In the patient group with septic AKI, dialysis should not be seen as a curative intervention, but rather as supportive therapy, preventing the patient from dieing from hyperkalaemia or fluid overload during the period the kidneys are temporarily failing. As a consequence, early dialysis, in the semantic meaning of 'intervention before support is needed', exposes patients to side effects of the treatment without really helping them. Problematic for correct interpretation of the data in nearly all studies, including the one by Chou and colleagues, is the fact that virtually all are retrospective. This complicates the interpretation at various levels. As strict clinical rules on the timing of initiation of dialysis were present in these ICUs during the collection of these data, all patients in fact started at the same 'time point' in their disease, that is, when they fulfilled one of the preset criteria. As such, the categorization 'early versus late' loses the semantic significance of a 'time-related event', and in fact no conclusions on timing can be made. Conclusions on the impact of 'early versus late initiation of dialysis' would only be justified when, at the moment patients fulfilled the criteria for dialysis, one group started RRT immediately while for the other group dialysis was delayed for one or more days. In the only available randomized controlled trials in this field, early versus late was defined by the urinary output versus biochemical values [5,6] or by magnitude of urinary output [7]. One important aspect of the current paper by Chou and colleagues [1] is that the RIFLE criteria have no value in determining the need for dialysis, as equal numbers of patients within the different RIFLE categories were apparently started on dialysis. Indeed, if RIFLE were a good predictor of need for dialysis, one would expect that there was a preponderance of RIFLE class 'I' or 'F' in the cohort of dialyzed patients, quod non. Unfortunately, the study does not provide data on the distribution of the different RIFLE categories in the non-dialyzed patients, but we would not be surprised that these RIFLE categories were exactly comparable to those in the dialyzed cohort. RIFLE is a scoring system developed to grade prognosis of acute renal injury, and although it performs quite well at the cohort level, its applicability to individual patient outcome is rather poor. The RIFLE criteria were not developed to predict the need for dialysis. This is even more true in the current study, as the most powerful component of the RIFLE criteria, urine output, was not taken into account. As a consequence, the correct conclusion of the current data should thus be that serum creatinine is not a good parameter to use for determining when to start dialysis in AKI patients, just as has been found in patients with chronic kidney disease [8]. The omission of urine output as a parameter is critical, especially as fluid overload (central venous pressure >12 mmHg) was a criterion to start dialysis. The combination of evaluation of fluid status and urine output, and especially the evolution over time of these two parameters, is probably one of the major decisive criteria to start dialysis at present. When the patient is euvolemic, or even volume overloaded, and still remains oliguric despite maximal support, one should not await further organ damage, and dialysis should be initiated [9]. In addition, as only patients who did actually start dialysis were included, it is difficult to guess what happened to patients with classes RIFLE 0 or I who did not start dialysis. It is likely that these patients had a better survival than those who did start dialysis, and then, the conclusion of the study would be that early initiation of dialysis based on RIFLE criteria is detrimental. Such a conclusion is different from the statement that early initiation of dialysis based on RIFLE criteria in patients with sepsis does not reduce mortality. In conclusion, the question whether dialysis in AKI should be started early or late remains unanswered. Maybe we cannot answer this question now because it may be the wrong question: as dialysis is supportive and not curative, patients either need dialysis, in which case it should not be delayed, or they do not need dialysis, in which case it can only harm. What we need is a set of accepted indications for dialysis in AKI. Once we have agreed on those, the timely initiation of dialysis in those who are predicted to inevitably progress to one of those conditions seems the most appropriate strategy. In contrast, with current practice, it seems unlikely that serum creatinine or another serum/urine-based biomarker will be one of those criteria.

Abbreviations

AKI: acute kidney injury; RRT: renal replacement therapy.

Competing interests

The authors declare that they have no competing interests.
  9 in total

1.  Cytokine removal during continuous hemofiltration in septic patients.

Authors:  A S De Vriese; F A Colardyn; J J Philippé; R C Vanholder; J H De Sutter; N H Lameire
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

2.  The initiation of renal-replacement therapy--just-in-time delivery.

Authors:  Norbert Lameire; Wim Van Biesen
Journal:  N Engl J Med       Date:  2010-06-27       Impact factor: 91.245

3.  When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study.

Authors:  James Tattersall; Friedo Dekker; Olof Heimbürger; Kitty J Jager; Norbert Lameire; Elizabeth Lindley; Wim Van Biesen; Raymond Vanholder; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2011-05-05       Impact factor: 5.992

4.  Defining urine output criterion for acute kidney injury in critically ill patients.

Authors:  Etienne Macedo; Rakesh Malhotra; Rolando Claure-Del Granado; Peter Fedullo; Ravindra L Mehta
Journal:  Nephrol Dial Transplant       Date:  2010-06-17       Impact factor: 5.992

5.  Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure.

Authors:  Maqsood M Elahi; Ming Yann Lim; Robin N Joseph; Ramana Rao V Dhannapuneni; Tomasz J Spyt
Journal:  Eur J Cardiothorac Surg       Date:  2004-11       Impact factor: 4.191

6.  Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery.

Authors:  Souichi Sugahara; Hiromichi Suzuki
Journal:  Hemodial Int       Date:  2004-10-01       Impact factor: 1.812

7.  Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial.

Authors:  Catherine S C Bouman; Heleen M Oudemans-Van Straaten; Jan G P Tijssen; Durk F Zandstra; Jozef Kesecioglu
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

Review 8.  A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis.

Authors:  Constantine J Karvellas; Maha R Farhat; Imran Sajjad; Simon S Mogensen; Alexander A Leung; Ron Wald; Sean M Bagshaw
Journal:  Crit Care       Date:  2011-02-25       Impact factor: 9.097

9.  Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury.

Authors:  Yu-Hsiang Chou; Tao-Min Huang; Vin-Cent Wu; Cheng-Yi Wang; Chih-Chung Shiao; Chun-Fu Lai; Hung-Bin Tsai; Chia-Ter Chao; Guang-Huar Young; Wei-Jei Wang; Tze-Wah Kao; Shuei-Liong Lin; Yin-Yi Han; Anne Chou; Tzu-Hsin Lin; Ya-Wen Yang; Yung-Ming Chen; Pi-Ru Tsai; Yu-Feng Lin; Jenq-Wen Huang; Wen-Chih Chiang; Nai-Kuan Chou; Wen-Je Ko; Kwan-Dun Wu; Tun-Jun Tsai
Journal:  Crit Care       Date:  2011-06-06       Impact factor: 9.097

  9 in total
  5 in total

1.  Regional variation in the incidence of dialysis-requiring AKI in the United States.

Authors:  Raymond K Hsu; Charles E McCulloch; Elaine Ku; R Adams Dudley; Chi-Yuan Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 8.237

2.  Timing of renal replacement therapy initiation by AKIN classification system.

Authors:  Tacyano T Leite; Etienne Macedo; Samuel M Pereira; Sandro R C Bandeira; Pedro H S Pontes; André S Garcia; Fernanda R Militão; Irineu M M Sobrinho; Livia M Assunção; Alexandre B Libório
Journal:  Crit Care       Date:  2013-04-02       Impact factor: 9.097

3.  Challenges and pitfalls when implementing renal replacement therapy in the ICU.

Authors:  Ravindra L Mehta
Journal:  Crit Care       Date:  2015-12-18       Impact factor: 9.097

4.  A unifying hypothesis and a single name for a complex globally emerging infection: hantavirus disease.

Authors:  J Clement; P Maes; K Lagrou; M Van Ranst; N Lameire
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-09       Impact factor: 3.267

5.  The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial.

Authors:  Stéphane Gaudry; David Hajage; Laurent Martin-Lefevre; Guillaume Louis; Sébastien Moschietto; Dimitri Titeca-Beauport; Béatrice La Combe; Bertrand Pons; Nicolas de Prost; Sébastien Besset; Alain Combes; Adrien Robine; Marion Beuzelin; Julio Badie; Guillaume Chevrel; Jean Reignier; Julien Bohé; Elisabeth Coupez; Nicolas Chudeau; Saber Barbar; Christophe Vinsonneau; Jean-Marie Forel; Didier Thevenin; Eric Boulet; Karim Lakhal; Nadia Aissaoui; Steven Grange; Marc Leone; Guillaume Lacave; Saad Nseir; Florent Poirson; Julien Mayaux; Karim Asehnoune; Guillaume Geri; Kada Klouche; Guillaume Thiery; Laurent Argaud; Jean-Damien Ricard; Jean-Pierre Quenot; Didier Dreyfuss
Journal:  Trials       Date:  2019-12-16       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.